Intervention not reported
There was no evidence of differences in the proportion of participants experiencing serious adverse events (for any of the comparisons Quality of evidence = very low1,2,3. · people undergoing liver resection
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse eventsd · adults with low back pain
1 finding from 1 review
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
Serious adverse events · Patients with acute low‐back pain
1 finding from 1 review
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
It is very uncertain whether anti‐TNF discontinuation changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).
1 finding from 1 review
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
It is very uncertain whether anti‐TNF disease activity–guided dose tapering changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).
1 finding from 1 review
Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents
Anti‐TNF dose reduction showed no clear difference in number of serious adverse events compared with anti‐TNF continuation (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events – not reported · people with a low platelet count
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events Up to 12 weeks' · Patients with acute low‐back pain
Paracetamol showed no clear difference in serious adverse events Up to 12 weeks' compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · postmenopausal women at lower risk of fractures1
Intermittent/cyclic etidronate 400 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.9 [0.52, 1.54]
Studies not reported
Moderate
Serious adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · postmenopausal women at lower risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
RR 0.74 [0.42, 1.3]
Studies not reported
Very low
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Serious adverse events · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection
1 finding from 1 review
Serious adverse events · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection
1 finding from 1 review
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Serious adverse events · acute gout
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found